Attainment of Canadian and European guidelines’ lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin
| Autor: | Amish P. Shah, Scott Conard, J. Lin, Andrew M. Tershakovec, Mary E. Hanson, Harold E. Bays, Lawrence A. Leiter |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
Apolipoprotein B biology business.industry Atorvastatin Urology nutritional and metabolic diseases General Medicine Canadian Cardiovascular Society Hydroxymethylglutaryl-CoA reductase Ezetimibe health services administration Post-hoc analysis HMG-CoA reductase biology.protein medicine media_common.cataloged_instance lipids (amino acids peptides and proteins) cardiovascular diseases European union business medicine.drug media_common |
| Zdroj: | International Journal of Clinical Practice. 64:1765-1772 |
| ISSN: | 1368-5031 |
| Popis: | Summary Background: Canadian and European treatment guidelines identify low-density lipoprotein cholesterol (LDL-C) as a primary treatment target for hypercholesterolaemia. Objectives: This post hoc analysis compared ezetimibe 10 mg (ezetimibe) added to atorvastatin vs. doubling the atorvastatin dose on achievement of the 2009 Canadian Cardiovascular Society (CCS) and the 2007 Joint European Prevention Guidelines primary and optional secondary lipid targets and high-sensitivity C-reactive protein (hs-CRP) levels. Methods: After stabilisation on atorvastatin, hypercholesterolaemic patients at moderately high risk (MHR) for coronary heart disease (CHD) not at LDL-C |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|